Portal:ExRNA/FeaturedPathways
From WikiPathways
(Difference between revisions)
(updating list) |
(changed order) |
||
Line 19: | Line 19: | ||
[http://dx.doi.org/10.1158/0008-5472.CAN-13-2066 Hu, et al. Notch3 pathway alterations in ovarian cancer] | [http://dx.doi.org/10.1158/0008-5472.CAN-13-2066 Hu, et al. Notch3 pathway alterations in ovarian cancer] | ||
|- | |- | ||
- | |width=100px|{{# | + | |width=100px|{{#pwimage:Pathway:WP2012|250px||miRs in Muscle Cell Differentiation}} |
|width=100px|{{#pwImage:Pathway:WP2011|250px||REBF and miR33 in cholesterol and lipid homeostasis}} | |width=100px|{{#pwImage:Pathway:WP2011|250px||REBF and miR33 in cholesterol and lipid homeostasis}} | ||
|width=100px|{{#pwImage:Pathway:WP1991|250px||SRF and miRs in Smooth Muscle Differentiation and Proliferation}} | |width=100px|{{#pwImage:Pathway:WP1991|250px||SRF and miRs in Smooth Muscle Differentiation and Proliferation}} | ||
Line 48: | Line 48: | ||
|width=100px|{{#pwimage:Pathway:WP673|250px||ErbB Signaling Pathway}} | |width=100px|{{#pwimage:Pathway:WP673|250px||ErbB Signaling Pathway}} | ||
|width=100px|{{#pwimage:Pathway:WP2261|250px||Signaling Pathways in Glioblastoma}} | |width=100px|{{#pwimage:Pathway:WP2261|250px||Signaling Pathways in Glioblastoma}} | ||
- | + | ||
|width=100px|{{#pwimage:Pathway:WP2059|250px||Alzheimers Disease}} | |width=100px|{{#pwimage:Pathway:WP2059|250px||Alzheimers Disease}} | ||
- | |||
|width=100px|{{#pwimage:Pathway:WP2371|250px||Parkinsons Disease}} | |width=100px|{{#pwimage:Pathway:WP2371|250px||Parkinsons Disease}} | ||
- | |width=100px|{{#pwimage:Pathway: | + | |- |
+ | |width=100px|{{#pwImage:Pathway:WP1544|250px||MicroRNAs in cardiomyocyte hypertrophy}} | ||
+ | |width=100px|{{#pwimage:Pathway:WP2512|250px||Integrated Lung Cancer Pathway}} | ||
|width=100px|{{#pwimage:Pathway:WP2338|250px||miRNA Biogenesis}} | |width=100px|{{#pwimage:Pathway:WP2338|250px||miRNA Biogenesis}} | ||
|width=100px|{{#pwimage:Pathway:WP2911|250px||miRNA targets in ECM and membrane receptors}} | |width=100px|{{#pwimage:Pathway:WP2911|250px||miRNA targets in ECM and membrane receptors}} | ||
|- | |- | ||
- | |width=100px|{{#pwimage:Pathway: | + | |width=100px|{{#pwimage:Pathway:WP1601|250px||Fluoropyrimidine Activity}} |
|width=100px|{{#pwimage:Pathway:WP2910|250px||Mecp2 and Associated Rett Syndrome}} | |width=100px|{{#pwimage:Pathway:WP2910|250px||Mecp2 and Associated Rett Syndrome}} | ||
|} | |} |
Revision as of 05:41, 28 May 2015
Image does not exist |
Image does not exist |
Image does not exist Ozpolat, et al. Liposomal siRNA nanocarriers for cancer therapy Thomas, et al. Eri1: a conserved enzyme at the crossroads of multiple RNA-processing pathways |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |
Image does not exist |